Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO GU 2022 | ASCO GU 2022

Meghana Pagadala • 17 Feb 2022
ASCO GU 2022 GU Cancers 2022
Genitourinary Cancer

Meghana Pagadala, BS, University of California San Diego, San Diego, CA, on what she was most looking forward to at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022. In particular, Meghana Pagadala was excited for the discussions on rare germline variation in renal cell carcinoma. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.

More from Meghana Pagadala

0:43
Estimating the risk of dying from PC with the PHS290 algorithm and how it can be improved upon
Meghana Pagadala • 17 Feb 2022
1:26
Polygenic hazard score predict risks of developing metastatic or fatal prostate cancer
Meghana Pagadala • 17 Feb 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals